Lilly, Incyte rheumatoid arthritis drug succeeds in late-stage study

Sept 29 (Reuters) - Eli Lilly and Co and Incyte Corp said a third late-stage study of their experimental rheumatoid arthritis drug met its main goal.

The drug, baricitinib, was more effective than the decades-old treatment methotrexate, after 24 weeks of treatment, in reducing signs and symptoms of the inflammatory disorder, the companies said on Tuesday.

(Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)

Advertisement